Leadership

Three co-founders, unrivaled scientific capability

In-San Kim

Co-Founder / MD. Ph.D.

Founding Visionary and Principal Technologist

  • MD. and Ph.D. from Kyungpook National University School of Medicine
  • Cancer research at M.D. Anderson Cancer Center KIST Fellow Research
  • Professor at KU-KIST Graduate School 
  • Expertise in Cancer Immunology and Nanovesicle Therapy
  • Published over 400 papers (h-index: 82)

Gi-Hoon Nam

Co-Founder / MD. Ph.D.

Chief Executive Officer

  • MD. from Korea University School of Medicine
  • Ph.D. from KU-KIST Graduate School
  • Research on cancer immunotherapy and nanovesicle engineering at KIST, the Dana-Farber Cancer Institute, and Harvard Medical School
  • Assistant Professor, Korea University College of Medicine 

Won-Yong Lee

Co-Founder / MD. Ph.D.
Chief Executive Officer

  • MD. from Seoul National University School of Medicine
  • Ph.D. from Sungkyunkwan University
  • Otolaryngologist, Head and Neck Surgery training at Samsung Medical Center 
  • Clinical Fellow, Seoul National University Hospital Assistant

Meet the TEAM


Team SHIFTBIO

is demonstrating the best teamwork for a common goal.

We respect the capabilities that each individual can demonstrate

and the synergy effect created through cooperation.

For successful drug development
We are organizing the Scientific Advisory Board(SAB)
by consulting with authorities in each field
and discussing with renowned experts around the world.

Drug Development Research

Thomas M. Roberts, PhD.
  • Former Chairman, Department of Cancer Biology at the Dana-Farber Cancer Institute 
  • Former Dean of Graduate Education at Harvard Medical School

Contributing to the research of Ciba-Geigy, Key role in the development of Gleevec, which is one of the first molecularly-targeted cancer therapies. 


 Extracellular Vesicle (EV) Research

Kenneth Whitaker Witwer, Ph.D.
  • Associate Professor, Johns Hopkins University School of Medicine
  • President-Elect, International Society for Extracellular Vesicles

World-class researcher in EVs 

For successful drug development
We are organizing
the Scientific Advisory Board(SAB)
by consulting with authorities in each field
and discussing with renowned experts around the world.

Drug Development Research

Thomas M. Roberts, PhD.
  • Former Chairman, Department of Cancer Biology at the Dana-Farber Cancer Institute 
  • Former Dean of Graduate Education at Harvard Medical School

Contributing to the research of Ciba-Geigy, Key role in the development of Gleevec, which is one of the first molecularly-targeted cancer therapies. 


 Extracellular Vesicle (EV) Research

Kenneth Whitaker Witwer, Ph.D.
  • Associate Professor, Johns Hopkins University School of Medicine
  • President-Elect, International Society for Extracellular Vesicles

World-class researcher in EVs